The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10326 malaria professionals are enjoying the free benefits of MalariaWorld today

anti-malarial drug

Anti-malarial effect of novel chloroquine derivatives as agents for the treatment of malaria

February 21, 2017 - 15:35 -- Open Access
Author(s): 
Seon-Ju Yeo, Dong-Xu Liu, Hak Sung Kim and Hyun Park
Reference: 
Malaria Journal 2017 16:80, 17 February 2017

CQ derivatives with substituents such as α,β-unsaturated amides and phenylmethyl group have enhanced anti-malarial activity against the CQ-resistant strain P. falciparum, and SKM13 is an excellent anti-malarial drug candidate in mice model.

Medical Treatment: 

A simple and inexpensive haemozoin-based colorimetric method to evaluate anti-malarial drug activity

August 15, 2012 - 08:14 -- Kabogo Ndegwa
Author(s): 
Men T, Huy N, Trang D, Shuaibu M, Hirayama K, Kamei K
Reference: 
Malaria Journal 2012, 11:272 (9 August 2012)

MalariaWorldThe haemozoin-based colorimetric assay can be considered as an alternative, simple, robust, inexpensive and convenient method, making it applicable in developing countries.

Medical Condition: 
Medical Treatment: 

Anti-malarial drug formulations and novel delivery systems: A review

May 4, 2011 - 11:45 -- Kabogo Ndegwa
Author(s): 
P. Murambiwa, B. Masola, T. Govender, S. Mukaratirwa, C.T. Musabayane
Reference: 
Acta Tropica, Volume 118, Issue 2, May 2011, Pages 71-79

Artemisinin combination therapies have decreased malaria associated morbidity and mortality in several parts of the world.

Medical Condition: 
Medical Treatment: 

Open Access | Implementation of a reference standard and proficiency testing programme by the World Wide Antimalarial Resistance Network (WWARN)

December 29, 2010 - 11:52 -- Kabogo Ndegwa
Author(s): 
Lourens C, Watkins WM, Barnes KI, Sibley CH, Guerin PJ, White NJ, Lindegardh N
Reference: 
Malaria Journal 2010, 9:375 (25 December 2010)

The proficiency testing programme is designed as a cooperative effort to help participating laboratories assess their ability to carry out drug analysis, resolve any potential problem areas and to improve their results - and, in so doing, to improve the quality of anti-malarial pharmacokinetic data published and shared with WWARN.

Medical Treatment: 

Open Access | SMS for Life: a pilot project to improve anti-malarial drug supply management in rural Tanzania using standard technology

November 2, 2010 - 06:32 -- Kabogo Ndegwa
Author(s): 
Barrington J, Wereko-Brobby O, Ward P, Mwafongo W, Kungulwe S
Reference: 
Malaria Journal 2010, 9:298 (27 October 2010)

The SMS for Life pilot provided visibility of anti-malarial stock levels to support more efficient stock management using simple and widely available SMS technology, via a public-private partnership model that worked highly effectively.

Technology: 
Country: 

Open Access | Factors determining anti-malarial drug use in a peri-urban population from malaria holoendemic region of western Kenya

October 30, 2010 - 12:14 -- Kabogo Ndegwa
Author(s): 
Watsierah CA, Jura WG, Oyugi H, Abong'o B, Ouma C
Reference: 
Malaria Journal 2010, 9:295 (26 October 2010)

This study demonstrates that consumers require access to correct and comprehensible information associated with use of drugs, including self-prescription.

Country: 
Medical Condition: 

Open Access | Opinion:CPP-ZFN: A potential DNA-targeting anti-malarial drug

September 17, 2010 - 14:35 -- Kabogo Ndegwa
Author(s): 
Vikrant Nain, Shakti Sahi, Anju Verma
Reference: 
Malaria Journal 2010, 9:258

Targeting of the Plasmodium genome using ZFN has great potential for the development of anti-malarial drugs. It allows the development of a single drug against all malarial infections, including multidrug-resistant strains.

Medical Treatment: 

Open Access | Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty

July 27, 2010 - 13:54 -- Kabogo Ndegwa
Author(s): 
Smith DL, Klein EY, McKenzie F, Laxminarayan R
Reference: 
Malaria Journal 2010, 9:217 (23 July 2010)

At a global scale, because of uncertainty about the time to the emergence of ACT resistance, there was a strong case for MFTs to guard against early failure.

Medical Condition: 
Medical Treatment: 

Pages

Subscribe to RSS - anti-malarial drug